Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.44 USD
Change Today -0.05 / -0.59%
Volume 602.2K
LXRX On Other Exchanges
Symbol
Exchange
LXRX is not on other exchanges.
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

lexicon pharmaceuticals inc (LXRX) Key Developments

Lexicon Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 08:00 AM

Lexicon Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Lexicon Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:40 AM

Lexicon Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Lonnel Coats, Chief Executive Officer, President and Director.

Lexicon Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Clinical Pipeline Update; Provides Financial Guidance for the Year 2015

Lexicon Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net loss of $28,076,000 or $0.04 per basic and diluted share compared to a net loss of $30,835,000 or $0.06 per basic and diluted share in the corresponding period in 2014. Total revenues were $1,792,000 compared to $277,000 reported a year ago. Loss from operations was $26,527,000 compared to $30,472,000 reported a year ago. The company revenue increased primarily due to revenues recognized from the license and collaboration agreement with Ipsen. The company completed enrollment in TELESTAR, its pivotal Phase 3 clinical trial of telotristat etiprate for patients with carcinoid syndrome. The company expects to announced top-line data from the TELESTAR trial in the third quarter of 2015. Telotristat etiprate is an inhibitor of tryptophan hydroxylase (TPH) that reduces peripheral serotonin production without affecting brain serotonin levels. The company will complete enrollment on April 30, 2015 in TELECAST, its companion study which is being conducted in order to obtain additional safety data. Lexicon has commenced enrollment of patients in the first of its two pivotal Phase 3 clinical trials of sotagliflozin for type 1 diabetes and is preparing to initiate screening in the second pivotal Phase 3 study. Sotagliflozin is a dual inhibitor of sodium-glucose transporters 1 and 2 (SGLT1 and SGLT2). In parallel with Phase 3 development, Lexicon is conducting a Phase 2 clinical trial of sotagliflozin in collaboration with JDRF focused on young adults with type 1 diabetes and high A1C, representative of a population of particularly high unmet need. The company expects contractual revenues from existing agreements in 2015 to be around $3 million. The company continue to expect its operating expenses in 2015 will be in the range of $130 million to $140 million. The company expects its net cash used in operations to be in the range of $150 million to $160 million.

Lexicon Pharmaceuticals, Inc. to Report Q1, 2015 Results on Apr 29, 2015

Lexicon Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 5:00 PM, US Eastern Standard Time on Apr 29, 2015

Lexicon Pharmaceuticals, Inc., Q1 2015 Earnings Call, Apr 29, 2015

Lexicon Pharmaceuticals, Inc., Q1 2015 Earnings Call, Apr 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LXRX:US $8.44 USD -0.05

LXRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.69 USD -0.08
Boston Scientific Corp $17.34 USD +0.09
CR Bard Inc $196.65 USD +3.55
Johnson & Johnson $100.21 USD +0.37
Medtronic PLC $78.39 USD +0.11
View Industry Companies
 

Industry Analysis

LXRX

Industry Average

Valuation LXRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.9x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LEXICON PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.